Navigation Links
CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
Date:1/31/2008

"may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new
'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
2. CuraGen Appoints Clinical Oncologist as VP of Medical Development
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. CuraGen Corporation Receives Notification from NASDAQ
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... 2, 2011 Myriant Technologies, Inc. (Myriant), a ... chemicals, announces the addition of J. Brian Ferguson ... Ferguson, 56, is the former CEO and Chairman ... engaged in the manufacture and sale of a ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), ... vaccines against cancers and infectious diseases, announced today that ... DNA vaccine for foot-and-mouth disease administered by Inovio,s proprietary ... Dr. Niranjan Y. Sardesai, Inovio,s Sr. VP of Research ...
... sharp object has put Canadian researchers at the National Institute ... Book of World Records. Only one atom at its ... sharpest man-made object. It is made of Tungsten and ... being evaluated for its commercial potential., "We did not start ...
Cached Biology Technology:Myriant Technologies, Inc. Announces J. Brian Ferguson to Join Advisory Board 2Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 2Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 3Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 4Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 5Inovio Pharmaceuticals' Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease 6
(Date:7/24/2014)... Mass. (July 24, 2014) For years, researchers and ... forming nearly any cell type in the bodycould provide ... treat them. Yet progress has been hampered by the ... studies to their human counterparts, in part because human ... mouse cells. , Now Thorold Theunissen, Benjamin Powell, and ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... available in German . ... and respond to threats to health, and to provide ... of the mechanism underlying immunologic memory, however, has remained ... to support the hypothesis that the persistence of immune ... stem-cell-like potential. Until now, there was no conclusive evidence, ...
Breaking Biology News(10 mins):Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3
... the third most common family of epidermal growth factor ... Little is known about cancers harboring these mutations aside ... inhibitors, impairing the development of effective targeted therapies. A ... the International Association for the Study of Lung Cancer,s ...
... visualizing Earth science data from a NASA and U.S. Geological ... the ability to tease out the small events that can ... computer program is able to find patterns previously buried within ... led to seeing for the first time in satellite imagery ...
... 2013 A new study has found that tamoxifen, ... features in a mouse model of Duchenne muscular dystrophy ... long-term improvement of the symptoms in boys with DMD, ... muscle wasting, respiratory and cardiac impairments, paralysis, and premature ...
Cached Biology News:Landsat senses a disturbance in the forest 2Landsat senses a disturbance in the forest 3Landsat senses a disturbance in the forest 4Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy 2
...
... receptors constitute the principal excitatory ... classes of glutamate receptors exist: ... Ionotropic glutamate receptors are oligomeric ... NMDA1-3, KAI-2) which comprise ligand-gated ...
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
Recommended fro Western blotting application...
Biology Products: